The Nigerian government is suing the world’s largest drug manufacturer, Pfizer, for allegedly carrying out illegal trials of an anti-meningitis drug that killed or disabled children.
Nigeria is demanding $7bn in damages from the US company for the families of children it says died or suffered serious side effects when the antibiotic Trovan was administered in the northern state of Kano during a meningitis outbreak in 1996. The Kano state government also has civil and criminal cases pending against Pfizer.
The Nigerian authorities say that 200 children were part of the Trovan experiment without the approval of local regulatory authorities. They allege that as many as 11 died as a result of the treatment and others developed conditions including brain damage and paralysis.
Trovan was approved in the US in 1997 for use by adults but not children. Two years later the US Food and Drug Administration warned that the drug could cause liver damage and it has since been discontinued.
In court papers filed in Abuja yesterday, the government accuses Pfizer of conducting illegal tests on children.
“The plaintiff contends that the defendant never obtained approval of the relevant regulatory agencies ... nor did the defendant seek or receive approval to conduct any clinical trial at any time before their illegal conduct,” it said.
A Pfizer spokesman in New York, Bryant Haskins, said in a statement that the drug was administered in accordance with Nigerian law.
“These allegations against Pfizer, which are not new, are highly inflammatory and not based on all the facts. We continue to maintain, in the strongest terms, that the Nigerian government was fully informed in advance of the clinical trial; that the trial was conducted appropriately, ethically and with the best interests of patients in mind; and that it helped save lives,” he said.
Pfizer has previously said that it obtained “verbal consent” from the parents of the affected children, and that the drugs were administered in a way that was “sound from medical, scientific, regulatory and ethical standpoints”.
Two years ago, a US court dismissed a lawsuit by several Nigerian families who allege that they were not sufficiently warned that their children could be affected by the antibiotic.
A civil and criminal suit by the Kano state government against Pfizer was postponed yesterday until next month. It is seeking $2bn in damages.
The Nigerian government is looking for compensation for the cost of treatment of the victims of the drug test and their families. It is also seeking $450m for what it says is the suspicion of western medicines created by the case.
The country’s health authorities say that the Pfizer controversy is partly responsible for many families in northern Nigeria refusing to allow their children to be vaccinated against polio. That in turn has been blamed for an outbreak that spread across parts of Africa. The Kano authorities also refused to distribute the polio vaccine.
Since you're here ...
... we want to thank the tens of thousands of readers who contributed to our year-end fundraising campaign. Thanks to you, we managed to beat our $1.25m goal, raising more than $1.5m to fund our journalism, which will remain free and open to all.
If you’d still like to support the Guardian in 2021, it’s not too late. Millions are flocking to the Guardian for open, independent, quality news every day. Readers in all 50 states and in 180 countries around the world now support us financially.
Donald Trump’s chaotic presidency is ending, but the forces that propelled him – from a misinformation crisis to a surge in white nationalism to a crackdown on voting rights – remain clear and present threats to American democracy. The need for fact-based reporting that highlights injustice and offers solutions is as great as ever. In the coming year, the Guardian will also confront America’s many systemic challenges – from the climate emergency to broken healthcare to rapacious corporations.
We believe everyone deserves access to information that’s grounded in science and truth, and analysis rooted in authority and integrity. That’s why we made a different choice: to keep our reporting open for all readers, regardless of where they live or what they can afford to pay. In these perilous times, an independent, global news organisation like the Guardian is essential. We have no shareholders or billionaire owner, meaning our journalism is free from commercial and political influence.
If there were ever a time to join us, it is now. Your funding powers our journalism. Make a gift now from as little as $1. Thank you.